• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2021 o Market outlook: Forecast for 2021 - 2026 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Type o Market segments o Comparison by Type o Polyvalent anti-venom - Market size and forecast 2021-2026 o Monovalent anti-venom - Market size and forecast 2021-2026 o Other anti-venom types - Market size and forecast 2021-2026 o Market opportunity by Type • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2021-2026 o Asia - Market size and forecast 2021-2026 o Europe - Market size and forecast 2021-2026 o ROW - Market size and forecast 2021-2026 o Key leading countries o Market opportunity By Geographical Landscape o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Bharat Serums and Vaccines Ltd. o Boehringer Ingelheim International GmbH o CSL Ltd. o Merck KGaA o Pfizer Inc. o Rare Disease Therapeutics Inc. o SERB Sarl o Serum Institute of India Pvt. Ltd. o VINS Bioproducts Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2021 - 2026 ($ million) • 13: Global market: Year-over-year growth 2021 - 2026 (%) • 14: Five forces analysis 2021 & 2026 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2021 • 21: Type - Market share 2021-2026 (%) • 22: Comparison by Type • 23: Polyvalent anti-venom - Market size and forecast 2021-2026 ($ million) • 24: Polyvalent anti-venom - Year-over-year growth 2021-2026 (%) • 25: Monovalent anti-venom - Market size and forecast 2021-2026 ($ million) • 26: Monovalent anti-venom - Year-over-year growth 2021-2026 (%) • 27: Other anti-venom types - Market size and forecast 2021-2026 ($ million) • 28: Other anti-venom types - Year-over-year growth 2021-2026 (%) • 29: Market opportunity by Type • 30: Customer landscape • 31: Market share By Geographical Landscape 2021-2026 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2021-2026 ($ million) • 34: North America - Year-over-year growth 2021-2026 (%) • 35: Asia - Market size and forecast 2021-2026 ($ million) • 36: Asia - Year-over-year growth 2021-2026 (%) • 37: Europe - Market size and forecast 2021-2026 ($ million) • 38: Europe - Year-over-year growth 2021-2026 (%) • 39: ROW - Market size and forecast 2021-2026 ($ million) • 40: ROW - Year-over-year growth 2021-2026 (%) • 41: Key leading countries • 42: Market opportunity By Geographical Landscape ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: Bharat Serums and Vaccines Ltd. - Overview • 50: Bharat Serums and Vaccines Ltd. - Business segments • 51: Bharat Serums and Vaccines Ltd. - Key offerings • 52: Bharat Serums and Vaccines Ltd. - Key customers • 53: Bharat Serums and Vaccines Ltd. - Segment focus • 54: Boehringer Ingelheim International GmbH - Overview • 55: Boehringer Ingelheim International GmbH - Business segments • 56: Boehringer Ingelheim International GmbH - Key offerings • 57: Boehringer Ingelheim International GmbH - Key customers • 58: Boehringer Ingelheim International GmbH - Segment focus • 59: CSL Ltd. - Overview • 60: CSL Ltd. - Business segments • 61: CSL Ltd. - Key offerings • 62: CSL Ltd. - Key customers • 63: CSL Ltd. - Segment focus • 64: Haffkine bio pharmaceutical Corp. Ltd. - Overview • 65: Haffkine bio pharmaceutical Corp. Ltd. - Product and service • 66: Haffkine bio pharmaceutical Corp. Ltd. - Key offerings • 67: Haffkine bio pharmaceutical Corp. Ltd. - Key customers • 68: Haffkine bio pharmaceutical Corp. Ltd. - Segment focus • 69: Merck KGaA - Overview • 70: Merck KGaA - Business segments • 71: Merck KGaA - Key offerings • 72: Merck KGaA - Key customers • 73: Merck KGaA - Segment focus • 74: Pfizer Inc. - Overview • 75: Pfizer Inc. - Business segments • 76: Pfizer Inc. - Key offerings • 77: Pfizer Inc. - Key customers • 78: Pfizer Inc. - Segment focus • 79: Rare Disease Therapeutics Inc. - Overview • 80: Rare Disease Therapeutics Inc. - Product and service • 81: Rare Disease Therapeutics Inc. - Key offerings • 82: Rare Disease Therapeutics Inc. - Key customers • 83: Rare Disease Therapeutics Inc. - Segment focus • 84: SERB Sarl - Overview • 85: SERB Sarl - Product and service • 86: SERB Sarl - Key offerings • 87: SERB Sarl - Key customers • 88: SERB Sarl - Segment focus • 89: Serum Institute of India Pvt. Ltd. - Overview • 90: Serum Institute of India Pvt. Ltd. - Product and service • 91: Serum Institute of India Pvt. Ltd. - Key offerings • 92: Serum Institute of India Pvt. Ltd. - Key customers • 93: Serum Institute of India Pvt. Ltd. - Segment focus • 94: VINS Bioproducts Ltd. - Overview • 95: VINS Bioproducts Ltd. - Product and service • 96: VINS Bioproducts Ltd. - Key offerings • 97: VINS Bioproducts Ltd. - Key customers • 98: VINS Bioproducts Ltd. - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations

Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., VINS Bioproducts Ltd.